- PP405 - Wikipedia
Pelage Pharmaceuticals was named after the French word for "coat of fur" and PP405 was named after the company and the 405 freeway that goes through Los Angeles [2][8] The first human clinical trials of PP405 started in 2023 in Orange County [2][24]
- PP405 Hair Loss Treatment: Trials, Mechanism Timeline
Learn what PP405 is, how it works for hair loss, clinical trial updates, expected release date, and how it compares to finasteride or minoxidil
- Pelage
PP405 targets stem cells to reawaken the dormant hair follicles and restore youthful appearance Also known as pattern hair loss, the most common type of hair loss in men and women Caused by a combination of genetics, hormones, age, and environmental factors
- Is PP405 the Miracle Hair Loss Drug Weve Been Promised?
So, when Pelage Pharmaceuticals began touting its novel hair loss drug, PP405, and the fawning headlines started to roll in (“ Did UCLA Just Cure Baldness? ” and “ The Great Unbalding
- What is PP405: A Promising Hair Loss Solution—But Not Yet
Let’s explore what PP405 is, how it compares to existing treatments, and why hair transplantation remains the gold standard —especially for moderate to advanced hair loss What Is PP405? PP405 is a small molecule identified by UCLA researchers as a potential activator of dormant hair follicles
- Did UCLA Just Cure Baldness?
In the first human trials, conducted in 2023, researchers found that application of PP405 as a topical medicine onto the scalp at bedtime for a week produced promising results Although cautious with actual data, the UCLA researchers labeled the results “statistically significant ”
- Pelage Pharmaceuticals Phase 3 Trials for PP405 in 2026
“The financing will support the continued advancement of Pelage’s lead program, PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss ”
- Hair Loss Therapy Shows Potential for Regeneration in Phase 2 Trial
The study was a randomized, multicenter, double-blind, vehicle-controlled phase 2a trial that evaluated the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients
|